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Abstract
Background: Age-standardized net survival provides an important population-based summary of cancer survival
that appropriately accounts for differences in other-cause mortality rates and standardizes the population age
distribution to allow fair comparisons. Recently, there has been debate over the most appropriate method for
estimating this quantity, with the traditional Ederer II approach being shown to have potential bias.
Methods: We compare lifetable-based estimates (Ederer II), a new unbiased method based on inverse probability of
censoring weights (Pohar Perme) and model-based estimates. We make the comparison in a simulation setting;
generating scenarios where we would expect to see a large theoretical bias.
Results: Our simulations demonstrate that even in relatively extreme scenarios there is negligible bias in
age-standardized net survival when using the age-standardized Ederer II method, modelling with continuous age or
using the Pohar Perme method. However, both the Ederer II and modelling approaches have some advantages over
the Pohar Perme method in terms of greater precision, particularly for longer-term follow-up (10 and 15 years).
Conclusions: Our results show that, when age-standardizing, concern over bias with the traditional methods is
unfounded. We have also shown advantages in using the more traditional and modelling methods.
Keywords: Net survival, Relative survival, Epidemiology
Background
Cancer survival is often compared between different
populations. For example, between regions [1], socio-
economic groups [2] or calendar periods [3]. There are
many studies that compare cancer survival between coun-
tries, for example the EUROCARE [4], CONCORD [5]
and International Cancer Benchmarking Partnership [6]
studies.
Comparison of cancer survival is complicated by mor-
tality due to other causes varying between the groups
being compared. This will impact on the probability of
actually dying of the cancer. Therefore comparisons of
cancer survival between populations usually attempt to
estimate net survival, which is interpreted as survival in
the hypothetical world where it is not possible to die from
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other causes [7]. This allows a ‘fair’ comparison of can-
cer survival. Net survival is something we never observe
as patients in the real world are at risk of death from
other causes. Therefore, estimation requires assumptions
to be made. The usual approach has been to use relative
survival to estimate net survival.
Age plays an important role in the comparison of can-
cer survival. For most cancers net survival decreases with
age. When comparing survival between populations it is
therefore essential to ‘adjust’ for differences in the age dis-
tribution. When a single summary measure is required,
traditional age standardization is used, where an estimate
of relative survival is obtained separately in age groups and
a weighted average calculated with the weights reflecting
an international standard population [8].
Often survival differences between groups vary by age.
For example, international comparisons for breast [9, 10],
colorectal [11], prostate [12] and lung cancer [13] showed
larger differences in relative survival with increasing age.
By just giving an overall average these important differ-
ences can be missed. However, age-standardized relative
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survival is still an important summary measure and will
continue to be used.
Net survival has traditionally been estimated using rel-
ative survival; the ratio of all-cause survival to expected
survival. Pohar Perme et al. showed the commonly used
Ederer II method and other methods are potentially
biased when interest lies in an overall average of net sur-
vival and suggest an alternative (the Pohar Permemethod)
[14]. There has been inconsistency in the definition of ‘rel-
ative survival’ which has been used to refer to an analysis
where all ages have been pooled together [14, 15]. Sim-
ilarly, the term ‘net survival’ has been used to describe
the average net survival in a population. However, the
concepts of net and relative survival exist at the individ-
ual level. In fact we argue that the Pohar-Perme method
is estimated in a relative survival framework and can
only be interpreted as average net survival under two key
assumptions that apply to all methods.
An alternative way to estimate net survival is to use
statistical modelling [16, 17]. Statistical modelling allows
various assumptions to be incorporated, for example pro-
portional excess hazards, only selected interactions or the
fact that the true net survival can never increase.
Figure 1 shows estimated net survival for cancer of
rectum in England for those age 75+ estimated using
three different methods described later (Ederer II, Pohar
Perme and model based). It illustrates three key issues,
(i) the methods give different estimates of net survival,
particularly for long term follow up; (ii) the Pohar-Pohar
estimate is more variable than the other methods; (iii)
the confidence intervals for the Pohar-Perme estimate are
wider.
We argue that the theoretical bias when using the
Ederer II method to estimate age group specific or
Fig. 1 Comparison of Different Approaches to Estimating Net Survival
(with 95% confidence intervals) for 2117 Men Aged 75+, Diagnosed
with Cancer of the Rectum in England between 1992 and 2007. The
Confidence Interval for the Pohar Perme Method is Shown by the
Shaded Area
age-standardized net survival is negligible and can effec-
tively be ignored in practice. However, there are some
advantages in terms of improved precision when using
Ederer II or statistical modelling over the Pohar Perme
method.
Methods
Excess mortality, relative survival and net survival
We explain key concepts through both the excess mortal-
ity rate and relative survival as this highlights differences
between the methods. The excess mortality rate for an
individual i is the difference between their all-cause mor-
tality rate, hi(t) and their expected mortality rate if they
did not have cancer, h∗i (t),
λi(t) = hi(t) − h∗i (t).
The subscripts, i, are important as both expected and
all-cause mortality varies between individuals, with age a
key factor. Expected mortality rates are usually obtained
from national or regional mortality statistics, stratified by
age, sex, calendar year and potentially other covariates.











where Si(t) and S∗i (t) are the all-cause survival and
expected survival functions. To interpret, Ri(t) as a net
probability of survival, SNi (t), i.e. in the hypothetical situ-
ation where it is not possible to die of other causes, two
assumptions are needed;
(i) Conditional independence between cancer and
non-cancer mortality.
(ii) Appropriate expected mortality information. This
means that the mortality rate due to other causes for
the cancer patients is the same as that in the
population lifetable.
All methods described below require these assump-
tions to be true. For example, conditional independence
is addressed by stratification, regression modelling or
weighting for relevant covariates. For the remainder of
this paper we take these assumptions as reasonable as our
main focus is on the different methods of estimation.
In summary, net survival can be estimated in a relative
survival framework under certain assumptions. However,
Eq. (1) is at the individual level and often it is desired
to present an average (marginal survival). The traditional
lifetable approaches have averaged the numerator and
denominator separately, which is not the same as taking
an average of individual relative survival and is a key rea-
son why traditional approaches have potential bias when
estimating marginal survival.
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Age-standardized relative survival
It is useful to obtain a summary measure of survival in a
population. This can be done by calculating the average
(or marginal) survival. For simplicity, we consider the sit-
uation where relative survival, Ri(t), only varies by age. An
internally age-standardized estimate is the average of the





where n is the number of study subjects. This estimates
the internally age-standardized net survival, SN(t) under
assumptions (i) and (ii). This is not the same as estimating
relative survival ignoring the effect of age.
Equation (2) gives the age-standardized relative survival
in a particular study population. However, since different
populations may have different age distributions, tradi-
tional external age-standardization is usually performed.
This forces the same age distribution on each population
through a weighted average of age-specific estimates of
relative survival. The usual external reference population
uses weights in five age groups as shown in Table 1 [8]. The
externally weighted estimate of age-standardized relative







where wsi is weight for subject i from the reference
population (Table 1) and ai gives the proportion in the age
group to which the ith subject belongs. The ratio, wsi/ai
will be higher than one in age groups under-represented
in the study population compared with the standard pop-
ulation and less than one for age groups over-represented.
Since there are only five different weights, in practice
Table 1 The three International Cancer Survival Standard (ICSS)
weights used for age-standardization of net survival [8]
Age ICSS 1a ICSS 2b ICSS 3c
15-44 years 0.07 0.28 0.60
45-54 years 0.12 0.17 0.10
55-64years 0.23 0.21 0.10
65-74 years 0.29 0.20 0.10
75+ years 0.29 0.14 0.10
aLip, tongue, salivary glands, oral cavity, oropharynx, hypopharynx, head and neck,
oesophagus, stomach, small intestine, colon, rectum, liver, biliary tract, pancreas,
nasal cavities, larynx, lung, pleura, breast, corpus uteri, ovary, vagina and vulva, penis,
bladder, kidney, choroid melanoma, non-Hodgkin lymphomas, multiple myeloma,
chronic lymphatic leukaemia, acute myeloid leukaemia, chronic myeloid leukaemia,
leukaemia, prostate
bNasopharynx, soft tissues, melanoma, cervix uteri, brain, thyroid gland, bone
cTestis, Hodgkin’s disease, acute lymphatic leukaemia
relative survival is estimated separately by age group and





where wsk is the weight in the kth age group and Rk(t) the
corresponding relative survival.
If the weights, wsk are replaced by the observed pro-
portion of subjects in each age group then Eq. (4) gives
an internally age-standardized estimate, i.e. a grouped
version of Eq. (2).
The Ederer II method
The Ederer II method [18] is estimated in a relative sur-
vival framework, i.e. the ratio of all-cause survival, S(t), to
expected survival, S∗(t). The relative survival, R(t) is,
R(t) = S(t)S∗(t)
We use an adaption of the Ederer II method and estimate
the all-cause and expected survival through back calcula-
tion from the all-cause and expected mortality rates. This
makes little difference in practice, but allows comparison
with the Pohar-Perme method and is similar to the exten-
sion of the Ederer II method to continuous time described
by Pohar Perme et al. [14].
Follow-up time is divided into a number of intervals and
the excess mortality rate, λj calculated in each interval by
obtaining the total number of deaths in the jth interval and
subtracting the expected number of deaths. Dividing by
the total number of person years converts the difference








where dij is the death indicator for subject i in interval j,
d∗ij is the expected number of deaths and yij is the time at
risk. d∗ij is calculated using p∗ij, the probability individual i
in interval j will survive a year given their attained age and
calendar year and other demographic factors,
d∗ij = − ln(p∗ij)yij.





where kj is the length of the jth interval. The relative





When calculated for the study population as a whole
the Ederer II method gives a biased estimate of internally
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age-standardized net survival unless there is no varia-
tion in expected or relative survival between different ages
[14, 19], a situation almost certainly not true. Hakulinen
et al. argued that unless there was substantial variation
in relative survival by age the bias would be small, but a
theoretical bias still exists [19].
When comparing populations, external age standard-
ization is used with relative survival calculated separately
in each age group. Any bias due to variation in relative and
expected survival will be reduced. Within each age group
the Ederer II method will give an unbiased estimate of the
age-specific net survival if there is no variation in relative
survival within each age group. This assumption is almost
certainly not true, but since narrow age groups are being
used the variation will be much reduced compared to the
all age estimate. The important question is whether this
assumption matters, as empirical observation has shown
that the Ederer II method gives a more precise estimate
than the Pohar Perme method for long-term estimates
[20, 21].
The Pohar Permemethod
The Pohar Perme method was developed to give an
unbiased estimate of internally age-standardized net sur-
vival [14]. The method estimates the internally age-
standardized relative survival, i.e. that defined in Eq. (2).
It can be interpreted as internally age standardized net
survival under assumptions (i) and (ii). The method gives
greater weight to individuals with a higher risk of other
cause mortality. For example, consider two individuals
aged 60 and 80 at diagnosis. If both are still alive 10
years after diagnosis, the 80 year old receives more weight
because similar individuals are more likely to have died
of other causes. We use an adaption of the method for
when survival time is recorded in monthly intervals [21].
The weight for subject i in interval j is the inverse of the
expected survival, S∗ij, sowPPij = 1/S∗ij. The excess mortality
rate in the jth interval is,
λPPj =
∑





This is converted to the survival scale in the same way









For comparisons between population groups external age-
standardization is required, so the Pohar-Perme estimate
is calculated separately in each age group and a weighted
average estimated using Eq. (4).
Brenner method
It is not possible to calculate traditionally age-
standardized relative survival unless all age-specific
estimates can be calculated, a problem more likely in
the oldest age group. The Brenner alternative method
calculates an ‘all age’ Ederer II estimate, with each subject
up- or down-weighted so the age distribution reflects the
reference population [22]. The weights, wBi are the same
as those used in Eq. (3).
The excess mortality rate for the jth interval incorporat-
ing these weights is,
λBj =
∑




The weights depend on the age distribution at diagno-
sis. The weighting does not overcome any potential bias
if there is substantial variation in relative survival by age.
The excess mortality rate is transformed to the relative
survival in the same way as above.
Modelling
There is growing use of statistical models for excess mor-
tality [16, 23]. Modelling has some advantages over non-
parametric estimates by allowing more detailed explo-
ration and quantification of differences between groups
and can include continuous covariates, such as age at diag-
nosis[10]. Modelling also allows more precise estimation
of parameters of interest by making assumptions. It is
also possible to obtain an average or weighted average of
individual predicted relative survival functions to obtain
internally or externally age-standardized estimates.
Models for excess mortality are of the following form,
hi(t) = h∗i (t) + λi(t)
Interest lies in how covariates affect the excess mortality
rate, λi(t). When age-standardizing relative survival only
the effect of age needs to be modelled. An internally age-
standardized estimate of relative survival is obtained using
Eq. (2) where relative survival is estimated for each subject
in the study population. An externally age-standardized
estimate is calculated using Eq. (3).
We use a flexible parametric survival model for the
excess mortality [23]. Through the use of restricted cubic
splines the model can capture just about any shape for
the baseline excess hazard [24]. It can also incorporate
continuous covariates, so the effect of age is captured in
more detail, and allow for non-proportional excess haz-
ards. The latter point is important as non-proportional
excess hazards is extremely common in these studies
and allows the change in the excess mortality rate as
a function of age to change as a function of follow-up
time.
Simulation study
The purpose of the simulation study is to quantify any
bias in the methods in situations when one would expect
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the traditional non-parametric lifetable based methods
to be biased, i.e. when there is variation in relative sur-
vival by age. We have deliberately chosen two scenarios
where there is substantial variation by age and, in prac-
tice, most cancer sites have far less variation. In addition
to quantifying bias we assess the variability in the different
estimates.
Times to death from cancer (net survival) and due to
other causes were generated for each individual with the
minimum value taken as the time to death. The simulation
strategy is outlined in Fig. 2.
Table 2 gives the true net survival at selected ages for
each scenario showing large variation by age. The true
internally and externally age-standardized estimates are
also shown. In the simulation relative survival is equiva-
lent to net survival at the individual level since (i) only age
affects relative survival and (ii) the population mortality
information used to analyse the data is the same as that
used to generate the data.
For each scenario 1000 data sets were generated and
estimates of internally and externally age-standardized
relative survival obtained using the various methods.
These are explained in more detail below.
For internal age-standardization the following methods
were used,
Ederer II (all age) combines all ages into a single group.
Time since diagnosis was split into monthly intervals (this
is often the detail cancer registries are prepared to release
their data).
Ederer II (standardized) obtains age group specific
estimates and uses internal age-standardization using
Eq. (4), with the observed proportions in each age group
as weights. Time since diagnosis was split into monthly
intervals.
Pohar Perme is calculated for the study population as
a whole. Time since diagnosis was split into monthly
intervals.
Model-based (grouped) uses a flexible parametric
model with grouped age and applying Eq. (2). The baseline
hazard was modelled using 5 df for the spline variables.
The effect of age was assumed to be non-proportional by
incorporating interactions with follow-up time (3 df for
each age group).
Model-based (continuous) uses a flexible parametric
model with continuous age. Restricted cubic splines were
used for modelling age (3 df) and applying Eq. (2).
The baseline hazard was modelled using 5 df. Non-
proportional excess hazards were incorporated through
time-dependent effects (3 df for each spline term). Given
the way in which the data were simulated, this can be
Fig. 2 Details of the Simulation Study [30, 31]
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Table 2 True value of net survival for the two scenarios at
selected ages at 1, 5, 10, and 15 years postdiagnosis
Age 1 year 5 years 10 years 15 years
Scenario 1
35 95.8 74.9 62.2 54.0
45 93.2 72.8 60.5 52.5
55 89.1 69.6 57.8 50.2
65 82.7 64.6 53.6 46.5
75 73.1 57.1 47.4 41.1
85 59.6 46.6 38.7 33.6
95 42.6 33.3 27.7 24.0
Internal 79.7 62.2 51.7 44.9
External 78.6 61.4 51.0 44.3
Scenario 2
35 92.4 83.8 77.9 73.7
45 89.9 78.8 71.4 66.2
55 86.6 72.5 63.5 57.3
65 82.4 64.8 54.1 47.2
75 77.0 55.7 43.7 36.3
85 70.2 45.3 32.7 25.4
95 62.0 34.4 22.1 15.7
Internal 81.2 63.3 52.8 46.1
External 80.6 62.3 51.8 45.1
considered over modelling, but it reflects the way models
would be applied in practice.
For external age-standardization the following methods
were used,
Ederer II (Brenner) combines all ages and uses the Bren-
ner alternative method to give an externally weighted
estimate.
Ederer II (standardized) obtains age group specific esti-
mates and uses external age-standardization using Eq. (4)
using the external reference weights.
Pohar Perme obtains age group specific estimates and
uses external age-standardization using Eq. (4) using the
external reference weights.
Model-based (grouped) uses a flexible parametric
model using grouped age and applying Eq. 3. This was the
same model as used for internal age-standardization, but
applies different weights for the predictions.
Model-based (continuous) uses a flexible parametric
model with continuous age and applying Eq. 3. This was
the same model as used for internal age-standardization
for the predictions.
Each method was compared to the the true value to give
the bias (expressed as difference in percentage points),
the mean square error (MSE) and the coverage [25]. The
Stata code for the simulations can be found in the online
Additional files 1 and 2.
Results
Internal and external age-standardization
Table 3 shows the bias, MSE and coverage for scenario 1.
The bias is low for all methods for both internal and exter-
nal age standardization. At five years the largest bias was
Table 3 Scenario 1: comparison of bias (bold font), mean square
error (normal font) and coverage (italic font) for the different
methods to estimate age-standardized net survival. Bias is
difference in percentage points









































(Continuous Age) 0.2559 0.6946 1.5279
95.3 93.3 92.6
Lambert et al. BMCMedical ResearchMethodology  (2015) 15:64 Page 7 of 13
less than 0.27 percentage points (model-based grouped
age). Coverage was good for all methods with the excep-
tion of the model-based grouped age estimate. With the
exception of model-based grouped age, there was more
variation in the Pohar-Perme estimate at 5, and particu-
larly 10 and 15 years, reflected in the larger MSEs. This
is demonstrated in a scatter plot of the estimates from
each simulation in Fig. 3 (internal age standardization)
and Fig. 4 (external age standardization). The smallest
variation is for the all-age Ederer II method.
Table 4 shows the bias, MSE and coverage for scenario
2 with Figs. 5 and 6 showing scatter plots of the estimates
from each simulation for internal and external standard-
ization respectively. One would expect more bias for the
Ederer II method in this scenario since variation by age
in excess mortality continues for the whole study follow-
up. This can be seen by the fact that the Ederer II all
age estimate (internal) and the Brenner method (exter-
nal) gives biased estimates. For example, a 1.91 and 2.80
percentage point difference for external age standardiza-
tion for 10 and 15 years respectively. However, the bias for
Ederer II using traditional age standardization is less than
0.3 percentage points. There is some bias for the model-
based grouped age estimate at a 0.94 and 1.10 percentage
Fig. 3 Scenario 1: Scatter Plot of Estimated Internally Age Standardized Net Survival for the 1000 Different Estimates for each of the Methods. The
True Value is Shown by a Reference Line


































































Fig. 4 Scenario 1: Scatter Plot of Estimated Externally Age Standardized Net Survival for the 1000 Different Estimates for each of the Methods. The
True Value is Shown by a Reference Line
point difference for 10 and 15 years respectively. Cover-
age is reasonable for the Pohar Perme, Ederer II traditional
age standardized and model-based continuous age. As for
scenario 1 the Pohar Perme method has a higher MSE
reflecting more variation in the estimate.
Age group-specific estimates
To estimate traditionally age standardized net survival
separate estimates are required within each age group. For
the four youngest age groups there is negligible bias and
broad agreement for all methods (data not shown). How-
ever, the oldest age group will generally show more bias
due to more variation in expected and relative survival in
this group. Furthermore, a greater proportion of patients
will die from other causes leading to low numbers as
follow-up time increases. Table 5 shows the bias, MSE and
coverage for the oldest age group for the different meth-
ods. Bias for Ederer II for scenario 2 is 0.51, 0.96 and 1.25
percentage points at 5, 10 and 15 years respectively. As
with the age standardized estimates, there is far greater
variation for the Pohar Perme method, particularly at 10
and 15 years reflected by the higher MSEs.
Discussion
We have shown through a simulation that when an esti-
mate of age-standardized net survival is required, Ederer
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Table 4 Scenario 2: comparison of bias (bold font), mean square
error (normal font) and coverage (italic font) for the different
methods to estimate age-standardized net survival. Bias is
difference in percentage points









































(Continuous Age) 0.281334 0.558352 1.049332
94.6 95.5 95.6
II, Pohar Perme and modelling with continuous age have
negligible bias. However, Ederer II and modelling have
greater precision than the Pohar Perme method, though
the increase in precision is small at 5 years.
We do not dispute the theoretical bias in the Ederer
II estimate shown by Pohar-Perme [14]. However, when
using traditional age-standardization age-group specific
estimates are obtained and within each age-group there
is far less variation in both expected and relative survival.
Thus, even in the extreme scenarios presented here, the
potential bias can be ignored. For longer term survival,
due to the impact of the weights of elderly subjects, the
Pohar Perme estimate has higher variability.
The traditionally age-standardized Ederer II estimate
has improved precision over the Pohar Perme estimate
since it makes assumptions about variability. The assump-
tions are there is no variation in expected survival or in
relative survival within an age group. The first assumption
is definitely not true and the second is unlikely to be. How-
ever, these assumptions are not very important in terms
of bias. Thus the ‘cost’ of the bias when using Ederer II in
traditional age standardization can effectively be ignored,
but there is a ‘benefit’ in precision for longer term sur-
vival. The difference between the methods is small at five
years, but can be seen at 10 and 15 years. For Scenario 1,
even the all-age Ederer II had negligible bias due to the
variation in age not persisting over follow-up time show-
ing that these assumptions are not that important [19].
The model-based grouped age approach showed some
bias, particularly for the more extreme scenario 2. The
grouping of age in a statistical model is more prone to bias
than when using the Ederer II method due to the different
ways of averaging within an age group.
The model-based continuous age approach was unbi-
ased and had improved precision due to making certain
assumptions. Firstly, the excess mortality rate is consid-
ered a smooth function rather than a step function. The
true net survival function can never increase and in prac-
tice the estimated relative survival curve when modelling
will be a decreasing function of time and not increase
due to chance like the Pohar-Perme and Ederer II meth-
ods. Secondly, the effect of age is treated as continuous
and estimates have greater precision than when grouping
age [26]. We used restricted cubic splines to approximate
the underlying excess mortality rate as these have been
shown to be unbiased in a wide range of scenarios [24]. If
interest is only in a single summary measure then we see
little advantage ofmodelling over the non-parametric esti-
mates. However, modelling allows greater understanding
of differences between groups of interest. From a single
statistical model it is possible to produce summary mea-
sures such as age standardized relative survival, but also
quantify how differences vary by time since diagnosis, by
age or by any other modelled covariate.
Age standardized relative survival is a weighted average
of five age groups. The four youngest groups has negli-
gible bias and it is the oldest age group that more likely
to be biased, but this group only contributes 29% of the
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Fig. 5 Scenario 2: Scatter Plot of Estimated Internally Age Standardized Net Survival for the 1000 Different Estimates for each of the Methods. The
True Value is Shown by a Reference Line
weight. When interest lies in age-specific estimates the
bias may be more important. For example, in our more
extreme scenario, the bias for Ederer II for those aged
75+ was around 1 percentage point at 10 and 15 years,
though the MSE was substantially lower than the Pohar
Perme estimate. This bias could be reduced by using more
finely split age groups, but then there would be the poten-
tial problem of having no patients at risk for longer term
follow-up, so traditional age standardization could not be
performed. When modelling age continuously this prob-
lem does not occur. An important issue here is whether
one should estimate long-term net survival for the elderly.
To estimate 15 year net survival in those aged 90, for
example, is probably not relevant as it is highly likely that
all would be dead by the age of 105. However, if one wants
a long-term average estimate for the full population then
an estimate in the oldest age group is required. All meth-
ods have problemswith estimation in the oldest age group.
For example, if at diagnosis there are a number of subjects
aged 90 or over, but by 4 years these people are all dead.
The Pohar Perme estimate has no one over the age of 90
to up weight and thus estimates are based on the survival
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Fig. 6 Scenario 2: Scatter Plot of Estimated Externally Age Standardized Net Survival for the 1000 Different Estimates for each of the Methods. The
True Value is Shown by a Reference Line
experience of a younger group. There is a similar problem
for the Ederer II and so the younger subjects remaining in
the age groups are used for longer term excess mortality
estimates. Modelling “borrows” information across both
age and follow-up time in the predictions of net survival
for older subjects.
Other authors have made strong statements that the
Pohar Perme estimate is preferable over Ederer II. How-
ever, some of these comparisons have been with the all
age Ederer II estimate rather than the traditionally age
standardized estimate [14, 15] or placed more emphasis
on bias than precision [15]. One paper calculates the dif-
ference between the Pohar Perme estimate and various
estimates and labels this ‘bias’ [27]. The Pohar Perme esti-
mate is subject to more random variation than the other
methods and this is an inappropriate use of the term ‘bias’.
A simulation study provides the appropriate framework
to quantify bias. One further issue is potential bias when
the age distribution changes over calendar time [28, 29].
This can lead to bias, but in most cases this will negligi-
ble. Firstly, it is unlikely the age distribution will change
as much as in the simulation studies (e.g. a sudden 10
year increase/decrease in the mean age at diagnosis [15]).
Secondly, it is not usual to pool so many calendar years
together since we would either stratify or model the effect
calendar year.
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Table 5 Comparison of bias (bold font), mean square error
(normal font) and coverage (italic font) for the different methods
to estimate age-standardized net survival for those aged 75+.
Bias is difference in percentage points

































(Continuous Age) 1.6218 4.6727 10.2586
94.0 95.2 94.6
Simulation studies only investigate a limited number of
scenarios. Our two scenarios were chosen as very extreme
cases due to the variation in net survival by age. The
majority of cancer sites will have far less variation. We
believe scenario 2 is more extreme than any site seen in
practice as the variation in the excess mortality rate by age
continues into the long term. Various studies have shown
that there is far more variation in the excess mortality rate
in the first year or so [9–13, 19]. As the bias is negligible in
this extreme case, any potential bias can be ignored in real
world applications. Our simulations use a sample size of
15,000. Bias will not be affected by sample size. However,
the variation in the Pohar Perme estimate seen in Fig. 1
will become more pronounced in smaller samples.
Conclusion
In summary, if interest is in a single summary measure
of survival we do not see a considerable advantage of the
Pohar Perme estimate over the age-standardized Ederer II
estimate and a benefit of the latter for longer term follow-
up due to improved precision. Our personal preference is
to use statistical modelling as it is possible to obtain both
simple summaries, such as age standardized estimates,
and a more detailed understanding of differences between
demographic groups.
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